The EPS miss and sequential test volume decline are negative signals for a pre-revenue-stage diagnostics company. However, the $45M proforma cash runway into 2027 removes near-term financing risk. Watch for Medicare coverage decision as the key catalyst — positive outcome could re-rate the stock significantly. The 18M share offering at $1.00 (below the $1.31 pre-offer price) adds ~26% dilution.
Price Chart
Executive Summary
Lucid Diagnostics reported Q1 2026 revenue of $1.3M (up 52% YoY from $0.8M) and a GAAP net loss of $0.17/share, which is a miss vs the $-0.06 consensus. The company processed 3,177 EsoGuard tests (down 13% QoQ from 3,664 in Q4 2025). Cash burn continues, but the balance sheet was strengthened by a $17M net equity offering in April, extending runway into 2027. The stock is likely to trade down on the EPS miss and sequential test volume decline, partially offset by the cash runway extension.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $1.3M vs $0.8M YoY (+52%) but below $1.5M in Q4 2025
- GAAP EPS -$0.17 vs consensus -$0.06 (miss of ~183%)
- EsoGuard tests processed: 3,177 in Q1 2026 vs 3,664 in Q4 2025 (-13% QoQ)
- Non-GAAP adjusted loss -$10.5M vs -$11.2M in Q1 2025 (improved YoY)
- Cash $27.9M at quarter end; proforma $45M after April 2026 $17M equity offering
- Cash runway extended into 2027, past expected Medicare reimbursement milestone
- April 2026 underwritten offering of 18M shares at $1.00/share, netting ~$17M
- Clinical practice guideline update at DDW recommending EsoGuard as only non-endoscopic test with high certainty
Financial Impact
EPS miss of ~$0.11 vs consensus; sequential test volume decline of 13%
Risk Factors
- Medicare coverage decision delayed or negative — would severely impact revenue trajectory
- Cash burn rate of ~$10-11M/quarter non-GAAP — runway only ~4 quarters at current pace
- Sequential test volume decline suggests commercial momentum may be stalling
- Heavy dilution from April 2026 offering (18M shares, ~26% of pre-offer float)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022877 |
| Document: form8-k.htm | 0001493152-26-022877 |
| Document: 0001493152-26-022877-index-headers.html | 0001493152-26-022877 |
| Document: 0001493152-26-022877-index.html | 0001493152-26-022877 |
| Document: 0001493152-26-022877.txt | 0001493152-26-022877 |
| 8-K Data (Synthetic) | 0001493152-26-022877 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4110 $0.5007 | ▼ −21.82% | ▼ −21.11% | $0.4508 (−9.68%) |
Oct 16, 2026 10d ago | 8-K | $0.3770 $0.3520 | ▲ +6.63% | ▲ +6.97% | $0.4508 (−19.58%) |
Sep 22, 2026 5w ago | 8-K | $0.8930 $0.8390 | ▼ −6.05% | ▼ −5.33% | $0.4508 (−49.52%) |
Aug 13, 2026 10w ago | 8-K | $0.9649 $0.9677 | ▲ +0.29% | ▲ +0.49% | $0.4508 (−53.28%) |
May 14, 2026 23w ago | 8-K | $1.02 $0.9910 | ▲ +2.84% | ▲ +1.62% | $0.4508 (+55.80%) |
Apr 24, 2026 26w ago | 8-K | $1.06 $1.04 | ▼ −1.89% | ▼ −1.40% | $0.4508 (−57.47%) |
Apr 23, 2026 26w ago | 8-K | $1.07 $1.06 | ▼ −0.93% | ▼ −1.10% | $0.4508 (−57.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers